pulm 3/27 pt 2
Swan-Ganz Catheter and Pulmonary Hypertension
Swan-Ganz Catheter
Definition: A special catheter threaded through neck veins into the pulmonary artery to measure pressures.
Provides measurement of pulmonary wedge pressure.
Normally measures 25 millimeters at rest.
Types of Pulmonary Hypertension
Five Classes of Pulmonary Hypertension
Impacts small pulmonary muscular arteries, leading to enlargement of arteries in the lungs.
Can be secondary to conditions such as:
Left-sided heart failure: Prolonged failure of the left side affects the right side, leading to pulmonary hypertension.
Lung parenchymal diseases: E.g., COPD (Chronic Obstructive Pulmonary Disease) can induce pulmonary hypertension.
Thrombotic or embolic phenomena: Blood clots in the lung.
Multi-factorial causes: Several contributing factors can lead to pulmonary hypertension.
Clinical Manifestations of Right-Sided Heart Failure
Patients with right-sided heart failure may present with:
Fatigue
Increased jugular venous pressure: Seen through the enlargement of jugular veins.
Backup of blood: Can back up to the liver, causing:
Ascites: Fluid accumulation in the abdominal cavity.
Hepatomegaly: Enlargement of the liver.
Splenomegaly: Enlargement of the spleen.
Peripheral edema: Fluid buildup in the systemic venous system.
Gastrointestinal distress: Reduced appetite, nausea.
Other Causes of Pulmonary Hypertension
Autoimmune causes: Conditions that incite inflammation of small pulmonary arteries, including:
Systemic sclerosis: Autoimmune disease impacting the skin and internal organs.
HIV and infections: Certain infections can worsen pulmonary health.
Obstructive sleep apnea: Often linked to obesity; increases abdominal pressure, reducing venous return and inducing hypoxemia.
Idiopathic pulmonary hypertension: Exclusion of other potential causes, may be due to genetic factors including mutations in the BMPR2 gene.
Genetic Aspects of Pulmonary Hypertension
BMPR2 Gene
Bone morphogenic protein receptor (BMPR2) related to transforming growth factor.
Pathophysiology: Mutations lead to endothelial dysfunction.
Causes proliferation of endothelial and small muscle cells, obstructing pulmonary vasculature.
Associated with concentric fibrosis of pulmonary arteries.
Found on chromosome 2.
Implications of Atherosclerosis and Other Conditions
Medial hypertrophy: A common feature across forms of pulmonary hypertension affecting muscular arteries in the pulmonary bed.
Atherosclerosis: Can cause occlusion of pulmonary arteries, worsening hypertensive conditions.
Recanalization: If atherosclerotic changes occur alongside recanalization, it can lead to embolic events that exacerbate the patient's condition.
Clinical Features of Idiopathic Pulmonary Hypertension
Demographics: Most commonly affects women aged 20-40 and children.
Symptoms: Dyspnea, fatigue, rarely chest pain, respiratory distress, cyanosis, right ventricular hypertrophy.
Mortality rate: Approximately 80% within 2-5 years if untreated.
Treatment Options for Pulmonary Hypertension
Short-term treatments:
Oxygen therapy: Improving oxygenation.
Calcium channel blockers: To reduce vascular resistance and improve flow.
Anticoagulants: Prevent blood clot formation.
Digoxin: Increases cardiac contractility.
Diuretics: Reduce fluid overload.
Advanced treatments:
Prostacyclin therapy: Mimics prostaglandin effects to induce vasodilation.
Lung transplant: Considered definitive therapy in advanced cases.
Diffuse Pulmonary Hemorrhagic Syndromes
Goodpasture's Syndrome
Affects lungs and kidneys; leads to hemoptysis and renal failure.
Mechanism: Autoantibodies target the alpha-3 chain of collagen IV, damaging the basement membranes of both organs.
Symptoms: Coughing up blood, rapid renal failure, lung consolidations seen on X-ray or CT.
Idiopathic pulmonary hemosiderosis: Rare disease, primarily affects children but can occur in adults; presents similarly to Goodpasture’s with hemoptysis and potential renal involvement.
Wegener's Granulomatosis
Characteristics: An autoimmune vasculitis affecting lungs and upper respiratory tract.
Symptoms: Nosebleeds, saddle nose deformity, hemoptysis, kidney failure.
Differential diagnosis: Distinguishing symptoms from Goodpasture's involves noting upper respiratory tract symptoms like sinusitis.
Management: Involves immunosuppressive therapy due to autoimmune nature of the disease.
Conclusion
Urgency of Treatment: Early and aggressive management of pulmonary hypertension is crucial to improve outcomes and prevent morbidity and mortality.